John Wass
YOU?
Author Swipe
View article: OR25-06 Pituitary gigantism: how much different from acromegaly? A comparison of clinical features and mortality in 3244 Patients
OR25-06 Pituitary gigantism: how much different from acromegaly? A comparison of clinical features and mortality in 3244 Patients Open
Disclosure: S. Kaniuka-Jakubowska: None. M. Kaszubowski: None. J. Davis: None. D. Abeyaratne: None. S.A. Akker: None. N. Archer: None. J. Ayuk: Ipsen. W. Drake: None. A. Grossman: None. M. Gurnell: Ipsen, Pfizer, Inc., Recordati. C.E. High…
View article: Identifying Knowledge Gaps in Individuals With Primary Adrenal Insufficiency: A Critical Step in Preventing Adrenal Crisis
Identifying Knowledge Gaps in Individuals With Primary Adrenal Insufficiency: A Critical Step in Preventing Adrenal Crisis Open
Objective Adrenal crisis is a potentially fatal complication of primary adrenal insufficiency (PAI) and the leading cause of death in this population. Knowledge and its application are crucial to prevention. This study aimed to assess know…
View article: Venous thromboembolism in patients with pituitary adenoma: UK multicentre cohort study
Venous thromboembolism in patients with pituitary adenoma: UK multicentre cohort study Open
Objective This study aims to assess risk of venous thromboembolism (VTE) in patients with Cushing's disease (CD) compared to acromegaly and non-functioning pituitary adenomas (NFPAs) and to investigate the timing and risk factors for VTE. …
View article: The Utility of Plasma Metanephrines to Optimise Adrenal Vein Sampling for Primary Aldosteronism: A Single Centre Experience
The Utility of Plasma Metanephrines to Optimise Adrenal Vein Sampling for Primary Aldosteronism: A Single Centre Experience Open
Background Primary aldosteronism (PA) is a prevalent yet frequently underdiagnosed cause of secondary hypertension, affecting up to 10% of hypertensive individuals and contributing to increased cardiovascular risk. Accurate diagnosis is vi…
View article: The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data
The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data Open
Background Despite steroid replacement therapy, patients with adrenal insufficiency (AI) experience excessive infections and related hospital admissions. However, data examining the evolution of admissions, healthcare resources utilisation…
View article: A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update Open
OBJECTIVE: The aim of the Acromegaly Consensus Group was to revise and update the consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013. PARTICIPANTS: The Consensus Group, convened by 11 Steering Committee…
View article: A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature
A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature Open
Osilodrostat is an oral steroidogenesis inhibitor used in the treatment of hypercortisolism. It works by inhibiting 11-beta-hydroxylase, a key enzyme in cortisol synthesis. As a consequence of drug action, adrenal insufficiency can be obse…
View article: Commissioning of Tier 3 obesity services by Integrated Care Boards in England: an analysis of responses to Freedom of Information requests
Commissioning of Tier 3 obesity services by Integrated Care Boards in England: an analysis of responses to Freedom of Information requests Open
Objectives This research surveyed Tier 3 adult weight management services in England commissioned by integrated care boards (ICBs) across England in financial year 2022-2023. Design Survey of public health services commissioned by ICBs gat…
View article: 7573 Cyclic Cushing’s Syndrome: Periodicity and Treatment Outcome in an International Multicenter Case Series
7573 Cyclic Cushing’s Syndrome: Periodicity and Treatment Outcome in an International Multicenter Case Series Open
Disclosure: E. Nowak: None. M. Fleseriu: Consulting Fee; Self; Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals. Grant Recipient; Self; Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals. Q. Zhang: None. S. Zhang: None. K.C. Yu…
View article: Approach to the Patient With Suspected Hypotonic Polyuria
Approach to the Patient With Suspected Hypotonic Polyuria Open
Investigation and management of hypotonic polyuria is a common challenge in clinical endocrinology. The 3 main causes, recently renamed to arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus), arginine vasopressin r…
View article: Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016
Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016 Open
Context Epidemiological studies involving patients with acromegaly have yielded conflicting results regarding cancer incidence and causes of mortality in relation to control of growth hormone (GH) excess. Objective The objective of this re…
View article: Standards of Care for Medical Management of Acromegaly in Pituitary Tumor Centers of Excellence (PTCOE)
Standards of Care for Medical Management of Acromegaly in Pituitary Tumor Centers of Excellence (PTCOE) Open
Purpose: A series of consensus guidelines on medical treatment of acromegaly have been produced in the last two decades. However, little information is available on their application in clinical practice. Furthermore, international standar…
View article: THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN
THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN Open
Disclosure: K. Isand: None. R.A. Feelders: None. T.C. Brue: None. M. Toth: None. T. Deutschbein: None. M. Reincke: None. M. Krsek: None. A. Santos: None. F. Demtroder: None. O. Chabre: None. C.J. Strasburger: None. J.A. Wass: None. S.M. We…
View article: Validation of criteria for defining Pituitary Tumors Centers of Excellence (PTCOE)
Validation of criteria for defining Pituitary Tumors Centers of Excellence (PTCOE) Open
Purpose The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for pituitary tumor centers of excellence (PTCOEs) based on expert consensus. To validate those previously proposed crite…
View article: Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines Open
ABT-263 inhibits the antiapoptotic proteins Bcl-2, Bcl-xL, and Bcl-w and has single-agent efficacy in numerous small cell lung carcinoma (SCLC) and leukemia/lymphoma cell lines in vitro and in vivo. It is currently in clinical trials for t…
View article: Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines Open
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
View article: Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines Open
Supplementary Tables 1-2 from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
View article: Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Data from Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines Open
ABT-263 inhibits the antiapoptotic proteins Bcl-2, Bcl-xL, and Bcl-w and has single-agent efficacy in numerous small cell lung carcinoma (SCLC) and leukemia/lymphoma cell lines in vitro and in vivo. It is currently in clinical trials for t…
View article: COVID‐19‐related adrenal haemorrhage: Multicentre UK experience and systematic review of the literature
COVID‐19‐related adrenal haemorrhage: Multicentre UK experience and systematic review of the literature Open
Objective Adrenal haemorrhage (AH) is an uncommon, usually incidental imaging finding in acutely unwell patients. AH has been reported during coronavirus disease 2019 (COVID‐19) infection and following ChAdOx1 nCoV‐19 (Oxford‐AstraZeneca) …
View article: Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus
Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus Open
Recent data show that patients with a diagnosis of diabetes insipidus (DI) are coming to harm. Here we give the rationale for a name change to arginine vasopressin deficiency and resistance for central and nephrogenic DI, respectively.
View article: LBMON62 Central Diabetes Insipidus From A Patients’ Perspective- From Management To Psychological Co-morbidities And Re-naming Of The Condition
LBMON62 Central Diabetes Insipidus From A Patients’ Perspective- From Management To Psychological Co-morbidities And Re-naming Of The Condition Open
Background Central diabetes insipidus (cDI) is a rare neuroendocrine condition characterized by deficiency of arginine vasopressin. Data about treatment-related side effects, psychological co-morbidities, and incidence of wrong management …